Statin use and risk of bladder cancer: A meta-analysis

Cancer Causes and Control

Volumn 24, Issue 4, 2013, Pages 769-776

  Zhang, Xiao Long ^a,b   Geng, Jiang ^a,b   Zhang, Xiao Peng ^a,b   Peng, Bo ^a,b   Che, Jian Ping ^a   Yan, Yang ^a   Wang, Guang Chun ^a   Xia, Sheng Qiang ^a   Wu, Yan ^b   Zheng, Jun Hua ^a,b  

^a TONGJI UNIVERSITY   (China)

^b NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Bladder cancer; Meta analysis; Risk; Statin

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PLACEBO;

ARTICLE; BLADDER CANCER; CANCER RISK; CASE CONTROL STUDY; COHORT ANALYSIS; DISEASE ASSOCIATION; DRUG USE; HUMAN; META ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW;

CASE-CONTROL STUDIES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; PROGNOSIS; RISK FACTORS; URINARY BLADDER NEOPLASMS;

EID: 84876472135     PISSN: 09575243     EISSN: 15737225     Source Type: Journal    
DOI: 10.1007/s10552-013-0159-3     Document Type: Article

References (40)

1. World Health Organization (2011) Cance Stats Cancer worldwide. Available: http://info.cancerresearchuk.org/cancerstats/world/. Accessed 22 Jan 2011
2. Jemal A, Bray F, Center MM, Ferlay J, Ward E et al (2011) Global cancer statistics. CA Cancer J Clin 61:69-90
3. National Cancer Institute (2011) SEER stat fact sheets: Bladder. Available: http://seer.cancer.gov/statfacts/html/urinb.html. Accessed Jan 22 2011
4. Mills EJ, Rachlis B, Wu P, Devereaux PJ, Arora P et al (2008) Primary prevention of cardiovascular mortality and events with statin treatments: a network meta-analysis involving more than 65,000 patients. J Am Coll Cardiol 52:1769-1781
5. Mihaylova B, Emberson J, Blackwell L, Keech A, Simes J et al (2012) The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet 380:581-590
6. Newman TB, Hulley SB (1996) Carcinogenicity of lipid-lowering drugs. JAMA 275:55-60
7. Keyomarsi K, Sandoval L, Band V, Pardee AB (1991) Synchronization of tumor and normal cells from G1 to multiple cell cycles by lovastatin. Cancer Res 51:3602-3609
8. Wong WW, Dimitroulakos J, Minden MD, Penn LZ (2002) HMG-CoA reductase inhibitors and the malignant cell: the statin family of drugs as triggers of tumor-specific apoptosis. Leukemia 16:508-519
9. Dimitroulakos J, Marhin WH, Tokunaga J, Irish J, Gullane P et al (2002) Microarray and biochemical analysis of lovastatin-induced apoptosis of squamous cell carcinomas. Neoplasia 4:337-346
10. Park HJ, Kong D, Iruela-Arispe L, Begley U, Tang D et al (2002) 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors interfere with angiogenesis by inhibiting the geranylgeranylation of RhoA. Circ Res 91:143-150
11. Weis M, Heeschen C, Glassford AJ, Cooke JP (2002) Statins have biphasic effects on angiogenesis. Circulation 105:739-745
12. Alonso DF, Farina HG, Skilton G, Gabri MR, De Lorenzo MS et al (1998) Reduction of mouse mammary tumor formation and metastasis by lovastatin, an inhibitor of the mevalonate pathway of cholesterol synthesis. Breast Cancer Res Treat 50:83-93
13. Kusama T, Mukai M, Iwasaki T, Tatsuta M, Matsumoto Y et al (2002) 3-Hydroxy-3-methylglutaryl-coenzyme a reductase inhibitors reduce human pancreatic cancer cell invasion and metastasis. Gastroenterology 122:308-317
14. Kamat AM, Nelkin GM (2005) Atorvastatin: a potential chemopreventive agent in bladder cancer. Urology 66:1209-1212
15. Clearfield M, Downs JR, Weis S, Whitney EJ, Kruyer W et al (2001) Air Force/Texas coronary atherosclerosis prevention study (AFCAPS/TexCAPS): efficacy and tolerability of long-term treatment with lovastatin in women. J Womens Health Gend Based Med 10:971-981
16. Graaf MR, Beiderbeck AB, Egberts AC, Richel DJ, Guchelaar HJ (2004) The risk of cancer in users of statins. J Clin Oncol 22:2388-2394
17. Kaye JA, Jick H (2004) Statin use and cancer risk in the General Practice Research Database. Br J Cancer 90:635-637
18. Strandberg TE, Pyorala K, Cook TJ, Wilhelmsen L, Faergeman O et al (2004) Mortality and incidence of cancer during 10-year follow-up of the Scandinavian Simvastatin Survival Study (4S). Lancet 364:771-777
19. Heart Protection Study Collaborative Group. The effects of cholesterol lowering with simvastatin on cause-specific mortality and on cancer incidence in 20,536 high-risk people: a randomised placebo-controlled trial [ISRCTN48489393]. BMC Med. 2005 Mar 16;3:6
20. Coogan PF, Rosenberg L, Strom BL (2007) Statin use and the risk of 10 cancers. Epidemiology 18:213-219
21. Farwell WR, Scranton RE, Lawler EV, Lew RA, Brophy MT et al (2008) The association between statins and cancer incidence in a veterans population. J Natl Cancer Inst 100:134-139
22. Haukka J, Sankila R, Klaukka T, Lonnqvist J, Niskanen L et al (2010) Incidence of cancer and statin usage-record linkage study. Int J Cancer 126:279-284
23. Jacobs EJ, Newton CC, Thun MJ, Gapstur SM (2011) Long-term use of cholesterol-lowering drugs and cancer incidence in a large United States cohort. Cancer Res 71:1763-1771
24. Kuo CC, Chiu HF, Lee IM, Kuo HW, Lee CT et al (2012) Statin use and the risk of bladder cancer: a population-based case-control study. Expert Opin Drug Saf 11:733-738
25. Friedman GD, Flick ED, Udaltsova N, Chan J, Quesenberry CP Jr et al (2008) Screening statins for possible carcinogenic risk: up to 9 years of follow-up of 361,859 recipients. Pharmacoepidemiol Drug Saf 17:27-36
26. Vinogradova Y, Coupland C, Hippisley-Cox J (2011) Exposure to statins and risk of common cancers: a series of nested case-control studies. BMC Cancer 11:409
27. Sato S, Ajiki W, Kobayashi T, Awata N (2006) Pravastatin use and the five-year incidence of cancer in coronary heart disease patients: from the prevention of coronary sclerosis study. J Epidemiol 16:201-206
28. Dale KM, Coleman CI, Henyan NN, Kluger J, White CM (2006) Statins and cancer risk: a meta-analysis. JAMA 295:74-80
29. Browning DR, Martin RM (2007) Statins and risk of cancer: a systematic review and metaanalysis. Int J Cancer 120:833-843
30. Emberson JR, Kearney PM, Blackwell L, Newman C, Reith C et al (2012) Lack of effect of lowering LDL cholesterol on cancer: meta-analysis of individual data from 175,000 people in 27 randomised trials of statin therapy. PLoS ONE 7:e29849
31. Kuoppala J, Lamminpaa A, Pukkala E (2008) Statins and cancer: a systematic review and meta-analysis. Eur J Cancer 44:2122-2132
32. Moher D, Liberati A, Tetzlaff J, Altman DG (2010) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int J Surg 8:336-341
33. Higgins JP, Green S (2011) Cochrane handbook for systematic reviews of interventions. http://www.cochrane-handbook.org/
34. Wells GA, Shea B, O'Connell D, Peterson J, Welch V, Losos M, Tugwell P (2012) The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. http://www.ohri.ca/programs/clinical- epidemiology/oxford.asp
35. Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327:557-560
36. Higgins JP, Thompson SG (2004) Controlling the risk of spurious findings from meta-regression. Stat Med 23:1663-1682
37. Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315:629-634
38. Begg CB, Mazumdar M (1994) Operating characteristics of a rank correlation test for publication bias. Biometrics 50:1088-1101
39. Rogers MJ (2000) Statins: lower lipids and better bones? Nat Med 6:21-23
40. Hamelin BA, Turgeon J (1998) Hydrophilicity/lipophilicity: relevance for the pharmacology and clinical effects of HMG-CoA reductase inhibitors. Trends Pharmacol Sci 19:26-37